Coronavirus Visualized

Mar 25, 2020 | Blog | 0 comments

Daniel Gigante

Brett Averso, CTO, and I recently had a follow up discussion on our first coronavirus chat. Brett provided visualizations and commentary on coronavirus (SARS-CoV-2), ACE2, SARS-CoV-2 with SARS overlay, and antibody fragments to help people better understand the threat we’re currently facing, as well as put it in its proper context. Brett also discussed the role AI can play in finding an effective treatment for COVID-19. Give it a watch below.

Timestamps

Spike Glycoprotein: [0:13]

What’s so special about coronavirus? [0:57]

Host Receptor Explanation/ACE2 [1:29]

Similarity with SARS [2:16]

Antibody Fragments [3:09]

Can we use AI to make antibodies effective in treating SARS reach SARS-CoV-2? [3:27]

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award

by | June 29, 2021 | Press Releases | 0 Comments

University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (Issuewire.com)  - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...
Read More

NY Bio-Computation Startup EVQLV Closes Financing Round

by | February 8, 2021 | Press Releases | 0 Comments

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...
Read More

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

by | February 1, 2021 | News | 0 Comments

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...
Read More

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

by | January 12, 2021 | Press Releases | 0 Comments

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...
Read More

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

by | December 16, 2020 | Press Releases | 0 Comments

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...
Read More

Pin It on Pinterest